CancerVax Corporation (NASDAQ: CNVX), a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment of cancer, and Micromet AG, one of the leading privately-held European biopharmaceutical companies focused on the development of antibody-based drugs, announced today the completion of their merger and the change of the combined company’s name to “Micromet, Inc.” The company is incorporated in Delaware and Micromet AG has become a wholly-owned subsidiary of Micromet, Inc. In connection with the merger, CancerVax effected a 1-for-3 reverse stock split of its common stock. The combined company’s common stock will trade on the Nasdaq National Market on a post-split basis under the new ticker symbol “MITI” beginning May 8, 2006.
